Trial Profile
Phase II safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2021
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LOGIK1401
- 15 Mar 2021 Status changed from active, no longer recruiting to completed.
- 18 Oct 2017 Results assessing efficacy of alectinib for patients with Alk rearrangement positive non-small cell lung cancer and a poor performance status presented at the 18th World Conference on Lung Cancer
- 23 Feb 2017 Results published in the Journal of Thoracic Oncology